These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 27650829)

  • 1. Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT.
    Cremers EM; van Biezen A; de Wreede LC; Scholten M; Vitek A; Finke J; Platzbecker U; Beelen D; Schwerdtfeger R; Volin L; Harhalakis N; Blijlevens N; Nagler A; Kröger N; de Witte T
    Ann Hematol; 2016 Dec; 95(12):1971-1978. PubMed ID: 27650829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.
    Lim ZY; Fiaccadori V; Gandhi S; Hayden J; Kenyon M; Ireland R; Marsh J; Ho AY; Mufti GJ; Pagliuca A
    Leuk Res; 2010 Jun; 34(6):723-7. PubMed ID: 19944463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study.
    Alessandrino EP; Della Porta MG; Bacigalupo A; Malcovati L; Angelucci E; Van Lint MT; Falda M; Onida F; Bernardi M; Guidi S; Lucarelli B; Rambaldi A; Cerretti R; Marenco P; Pioltelli P; Pascutto C; Oneto R; Pirolini L; Fanin R; Bosi A
    Haematologica; 2010 Mar; 95(3):476-84. PubMed ID: 19903678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation
    Cremers EMP; de Witte T; de Wreede L; Eikema DJ; Koster L; van Biezen A; Finke J; Socié G; Beelen D; Maertens J; Nagler A; Kobbe G; Ziagkos D; Itälä-Remes M; Gedde-Dahl T; Sierra J; Niederwieser D; Ljungman P; Beguin Y; Ozkurt ZN; Anagnostopoulos A; Jindra P; Robin M; Kröger N
    Leuk Lymphoma; 2019 Oct; 60(10):2404-2414. PubMed ID: 30997844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34
    Barba P; Ratan R; Cho C; Ceberio I; Hilden P; Devlin SM; Maloy MA; Barker JN; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Ponce DM; Sauter C; Tamari R; van den Brink MRM; Young JW; O'Reilly RJ; Giralt SA; Perales MA
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):67-74. PubMed ID: 27789361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina.
    Basquiera AL; Pizzi S; Correas AG; Longo PG; Goldman WC; Prates MV; Formisano S; Kusminisky G; Feldman L; Berretta AR; García JJ; Staciuk R
    Pediatr Blood Cancer; 2015 Jan; 62(1):153-7. PubMed ID: 25264233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome.
    Radujkovic A; Becker N; Benner A; Penack O; Platzbecker U; Stölzel F; Bornhäuser M; Hegenbart U; Ho AD; Dreger P; Luft T
    Oncotarget; 2015 Oct; 6(33):35095-106. PubMed ID: 26360778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
    Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
    Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
    Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation.
    Wermke M; Schmidt A; Middeke JM; Sockel K; von Bonin M; Schönefeldt C; Mair S; Plodeck V; Laniado M; Weiss G; Schetelig J; Ehninger G; Theurl I; Bornhäuser M; Platzbecker U
    Clin Cancer Res; 2012 Dec; 18(23):6460-8. PubMed ID: 22991415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis.
    Konuma T; Shimomura Y; Ozawa Y; Ueda Y; Uchida N; Onizuka M; Akiyama M; Mori T; Nakamae H; Ohno Y; Shiratori S; Onishi Y; Kanda Y; Fukuda T; Atsuta Y; Ishiyama K;
    Hematol Oncol; 2019 Feb; 37(1):85-95. PubMed ID: 30370627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity.
    Lee JH; Lee JH; Lim SN; Kim DY; Kim SH; Lee YS; Kang YA; Kang SI; Jeon MJ; Seol M; Seo EJ; Chi HS; Park CJ; Jang S; Yun SC; Lee KH
    Bone Marrow Transplant; 2010 Mar; 45(3):450-7. PubMed ID: 19668236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
    Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
    Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC.
    Caulier A; Drumez E; Gauthier J; Robin M; Blaise D; Beguin Y; Michallet M; Chevallier P; Bay JO; Vigouroux S; Desbrosses Y; Cornillon J; Nguyen S; Dauriac C; de Latour RP; Lioure B; Rohrlich PS; Carré M; Bourhis JH; Huynh A; Suarez F; Garnier F; Duhamel A; Yakoub-Agha I
    Curr Res Transl Med; 2019 Feb; 67(1):8-15. PubMed ID: 30206045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Damaj G; Mohty M; Robin M; Michallet M; Chevallier P; Beguin Y; Nguyen S; Bories P; Blaise D; Maillard N; Rubio MT; Fegueux N; Cornillon J; Clavert A; Huynh A; Adès L; Thiébaut-Bertrand A; Hermine O; Vigouroux S; Fenaux P; Duhamel A; Yakoub-Agha I
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1349-55. PubMed ID: 24838178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.
    Scheid C; de Wreede L; van Biezen A; Koenecke C; Göhring G; Volin L; Maertens J; Finke J; Passweg J; Beelen D; Cornelissen JJ; Itälä-Remes M; Chevallier P; Russell N; Petersen E; Milpied N; Richard Espiga C; Peniket A; Sierra J; Mufti G; Crawley C; Veelken JH; Ljungman P; Cahn JY; Alessandrino EP; de Witte T; Robin M; Kröger N
    Bone Marrow Transplant; 2017 Nov; 52(11):1519-1525. PubMed ID: 28892084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.